Global Companion Diagnostics for Oncology Market

Companion Diagnostics for Oncology Market Size, Share, Growth Analysis, By Component(Products, and Services), By End User(Hospitals, Pathology/Diagnostic Laboratories, and Academic Medical Centers), By Indication(Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia), By Technology(Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)), By Region - Industry Forecast 2024-2031

Q: What is the global market size of Companion Diagnostics for Oncology Market?

Global Companion Diagnostics for Oncology Market size was valued at USD 3.1 billion in 2022 and is poised to grow from USD 3.5 billion in 2023 to USD 9.31 billion by 2031, growing at a CAGR of 13% in the forecast period (2024-2031).

Report ID: SQMIG35B2205 | Region: Global | Published Date: May, 2024
Pages: 215 | Tables: 122 | Figures: 76

Companion Diagnostics for Oncology Market Regional Insights

North America is slated to hold sway over global companion diagnostics for oncology demand outlook across the forecast period. This dominance can be attributed to surging prevalence of different cancers and high investments in oncology research are key factors that allow North America to account for a dominant stance in the global companion diagnostics for oncology marketplace. High availability of grants and subsidies for oncology research are also helping North America to maintain its dominance. The United States and Canada are projected to be the leading markets for companion diagnostics for oncology providers in this region.

High emphasis on healthcare infrastructure development and growing approval of novel oncology treatments and medical devices help Asia Pacific region become the fastest-growing regional market in the world. Supportive government initiatives to promote oncology R&D are also slated to create new opportunities for companion diagnostics providers based in this region going forward. China, India, and Japan are slated to be the top markets for companion diagnostics for oncology companies operating in the Asia Pacific region.

Companion Diagnostics for Oncology Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Companion Diagnostics for Oncology Market size was valued at USD 3.1 billion in 2022 and is poised to grow from USD 3.5 billion in 2023 to USD 9.31 billion by 2031, growing at a CAGR of 13% in the forecast period (2024-2031).

Companion diagnostics for oncology market players should solely focus on R&D to foster innovation and stand out from the competition. The requirement of huge amount of capital to enter this market makes it a difficult one for start-ups and new companies looking to innovate. Companion diagnostics for oncology providers can also emphasize improving the reimbursement scenario for companion diagnostics to maximize their revenue generation potential in the long run. 'F. Hoffmann-La Roche Ltd.', 'QIAGEN N.V.', 'ARUP Laboratories', 'Biocartis', 'Exact Sciences', 'Myriad Genetics Inc.', 'Sysmex Corporation', 'Abbott', 'Genedrive', 'Genomic Health', 'Archer Dx', 'Agilent Technologies Inc.', 'bioMérieux SA', 'Thermo Fisher Scientific Inc.', 'Invivoscribe Inc.', 'Guardant Health', 'Foundation Medicine', 'Illumina Inc.', 'Amoy Dx'

Precision medicine technologies are being rapidly developed and supplemented by high investments in medical R&D. Growing demand for personalized cancer therapies to minimize side effects will also boost the demand for companion diagnostics for oncology in the future.

Biomarker Discovery: Companion diagnostics for oncology companies should focus on discovering new biomarkers to expand thier business scope and revenue generation potential. Using advanced genomic and proteomic techniques and technologies, companion diagnostics for oncology companies can leverage biomarker discovery to their advantage and boost market growth in the future.

North America is slated to hold sway over companion diagnostics for oncology demand outlook across the forecast period. This dominance can be attributed to surging prevalence of different cancers and high investments in oncology research are key factors that allow North America to account for a dominant stance in the companion diagnostics for oncology marketplace. High availability of grants and subsidies for oncology research are also helping North America to maintain its dominance. The United States and Canada are projected to be the leading markets for companion diagnostics for oncology providers in this region.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Companion Diagnostics for Oncology Market Regional Insights

Companion Diagnostics for Oncology Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Companion Diagnostics for Oncology Market?

Who are the key vendors in the Companion Diagnostics for Oncology Market?

What is the key driver of Companion Diagnostics for Oncology Market?

What is the key market trend for Companion Diagnostics for Oncology Market?

Which region accounted for the largest share in Companion Diagnostics for Oncology Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300